Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease
NCT00548912 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL
Last updated 2021-12-09
Summary
The hypothesis of this trial is to assess the effect of spironolactone on heart size and mass
Conditions
- Kidney Failure, Chronic
Interventions
- DRUG
-
Spironolactone
Sponsors & Collaborators
-
Dawnmarie DeFazio
lead OTHER
Principal Investigators
-
Richard Marcus · West Penn Allegheny Health System
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-10-31
- Primary Completion
- 2008-10-31
- Completion
- 2008-10-31
Countries
- United States
Study Locations
More Related Trials
-
Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy
NCT00125437 ·Status: TERMINATED ·Phase: NA
-
Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?
NCT00291720 ·Status: COMPLETED ·Phase: PHASE2
-
Early Aldosterone Blockade in Acute Heart Failure: An Exploratory Safety Study
NCT02299726 ·Status: WITHDRAWN ·Phase: PHASE2
-
Gender-Based Differences in Heart Failure Hospitalizations Among Patients With Heart Failure Treated With Spironolactone
NCT06641284 ·Status: COMPLETED
-
Specific Blockage of Angiotensine 2 and Podocyturia in Glomerular Nephropathies With Hypertension and Proteinuria
NCT00369538 ·Status: SUSPENDED ·Phase: PHASE4
-
Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance
NCT02585843 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Mineralocorticoid Receptor Antagonists in End Stage Renal Disease
NCT01691053 ·Status: COMPLETED ·Phase: PHASE2
-
A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure
NCT03984591 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
Spironolactone in Adult Congenital Heart Disease
NCT01069510 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy
NCT02948998 ·Status: UNKNOWN ·Phase: PHASE4
-
Cardiovascular Evaluation of Adult PHA 1 Patients
NCT00646828 ·Status: COMPLETED
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
NCT05030545 ·Status: RECRUITING ·Phase: PHASE4
-
Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan
NCT00602004 ·Status: COMPLETED ·Phase: NA
-
Association of Diuretics With Change in Extracellular Volume, Natriuretic Peptides, Symptoms, and Cardiovascular Outcomes in CKD
NCT04192110 ·Status: WITHDRAWN ·Phase: PHASE4
-
Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing
NCT07281014 ·Status: RECRUITING ·Phase: PHASE4
-
Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications
NCT01406015 ·Status: COMPLETED ·Phase: NA
-
Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
NCT02235077 ·Status: COMPLETED ·Phase: PHASE2
-
Aldosterone Blockade in Heart Failure
NCT00523757 ·Status: COMPLETED ·Phase: PHASE3
-
Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation
NCT05498181 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy of Diuretics in Kidney Disease
NCT04542304 ·Status: TERMINATED ·Phase: PHASE2
-
Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension
NCT05925569 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Spironolactone Combined With Captopril and Carvedilol for the Treatment of Pulmonary Arterial Hypertension
NCT00240656 ·Status: COMPLETED ·Phase: PHASE1
-
Hypertension in Hemodialysis Patients (Aim 3)
NCT00582114 ·Status: TERMINATED ·Phase: PHASE3
-
Protocolized Diuretic Strategy in Cardiorenal Failure
NCT01921829 ·Status: TERMINATED ·Phase: PHASE4
-
Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease
NCT00865124 ·Status: COMPLETED ·Phase: NA